Top Small Cap Pharma Stocks in India by Market Capitalization

    Listen to our Podcast: Grow your wealth and keep it secure.

    0:00 / 0:00

    This blog explores the top small-cap pharmaceutical stocks in India based on market capitalization, focusing on their features, and industry dynamics to be aware of before investing. Small-cap pharma stocks represent companies with a market capitalization of less than ₹5,000 crore. These stocks often offer niche products and high growth potential, making them attractive for investors using tools like a demat account or trading account. Additionally, the blog highlights trends in the Indian pharma sector and key factors influencing investment decisions.

    Top 5 Small Cap Pharma Stocks in India You Should Know

    This table ranks leading small cap pharmaceutical companies by market capitalization, including their current price, net profit, and valuation ratio to provide a snapshot of scale and profitability.

    Company Name

    Market Cap (₹ Cr)

    CMP (₹)

    P/E Ratio

    Net Profit (₹ Cr)

    SPARC

    4,721.14

    145.48

    -79.71

    Unichem Labs.

    4,019.11

    570.85

    47.5

    57.85

    Orchid Pharma

    3,650.25

    719.70

    33.08

    20.78

    Sequent Scientific

    3,433.64

    137.18

    228.03

    6.48

    RPG Life Sciences

    3,413.57

    2,063.95

    35.73

    34.93

    Source: Screener as of 14 Apr’25

    Overview of Small Cap Pharma Stocks

    This brief table compares small cap pharma companies on operational returns and stock performance over the last six months.

    Company Name

    Market Cap (₹ Cr)

    ROCE (%)

    6M Return (%)

    SPARC

    4,721.14

    7.58

    -31.73

    Unichem Labs.

    4,019.11

    14.47

    -23.5

    Orchid Pharma

    3,650.25

    9.37

    -47.22

    Sequent Scientific

    3,433.64

    0.44

    -30.14

    RPG Life Sciences

    3,413.57

    34.65

    -27.03

    Source: Screener

    Sun Pharma Advanced Research Company Ltd (SPARC)

    Sun Pharma Advanced Research Company Ltd (SPARC) operates as a biopharmaceutical firm focused on innovation-led drug discovery and development. It primarily engages in creating novel drug delivery systems (NDDS) and new chemical entities (NCEs). Despite its focus on R&D, the company has been facing financial challenges with recurring losses and high valuations relative to its book value.

    This table summarizes the core financial and valuation indicators for SPARC as per the latest available data.

    Metric

    Value

    Market Capitalisation

    ₹4,721 crore

    Revenue

    ₹61.1 crore

    Net Profit

    -₹391 crore

    Book Value Multiplier

    37.8x

    Promoter Holding

    65.7%

    Interest Coverage Ratio

    Low

    Source: Screener

    Highlights:

    ● Negative profitability despite revenue generation.

    ● High promoter holding at 65.7%.

    ● Stock trades significantly above its book value​.

    Unichem Laboratories Ltd

    Unichem Laboratories Ltd is an Indian pharmaceutical company with a presence in domestic and international markets. The company manufactures active pharmaceutical ingredients (APIs) and formulations. While its revenue base is modest, its financial performance over the years has been underwhelming, with losses and poor return metrics.

    This table provides an overview of Unichem Labs' key performance indicators.

    Metric

    Value

    Market Capitalisation

    ₹4,019 crore

    Revenue

    ₹1,919 crore

    Net Profit

    -₹37.6 crore

    5-Year Sales Growth

    7.64%

    Return on Equity (3-Year Avg)

    -2.33%

    Promoter Holding

    70.2%

    Source: Screener

    Highlights:

    ● Weak sales growth over five years.

    ● Negative average return on equity.

    ● High promoter stake at 70.2%​.

    Sequent Scientific Ltd

    Sequent Scientific Ltd operates in the animal healthcare space and is known for veterinary pharmaceutical products. The company has demonstrated profitability and steady revenue, although its interest coverage ratio remains a concern.

    This table reflects Sequent Scientific’s financial summary based on the provided report.

    Metric

    Value

    Market Capitalisation

    ₹3,434 crore

    Revenue

    ₹1,511 crore

    Net Profit

    ₹23.2 crore

    Book Value Multiplier

    5.05x

    Promoter Holding

    52.6%

    Interest Coverage Ratio

    Low

    Source: Screener

    Highlights:

    ● Consistent profitability.

    ● Moderate valuation relative to book value.

    ● Promoter holding at 52.6%​.

    RPG Life Sciences Ltd

    RPG Life Sciences Ltd is engaged in pharmaceutical manufacturing and marketing across domestic and international markets. The company is financially sound, with a rising profit trend and strong promoter interest.

    The table below outlines key financial metrics for RPG Life Sciences.

    Metric

    Value

    Market Capitalisation

    ₹3,414 crore

    Revenue

    ₹637 crore

    Net Profit

    ₹79.1 crore

    Book Value Multiplier

    9.00x

    Promoter Holding

    73.0%

    Source: Screener

    Highlights:

    ● Strong revenue-to-profit ratio.

    ● Promoter holding is one of the highest among peers.

    ● Trades at a higher multiple compared to book value​.

    Orchid Pharma Ltd

    Orchid Pharma Ltd operates in the antibiotics and critical care segment. It has posted profits recently, but concerns remain regarding dividend payouts and valuation. Despite the profit track, the company has yet to distribute dividends.

    The following table displays Orchid Pharma’s current financial position.

    Metric

    Value

    Market Capitalisation

    ₹3,650 crore

    Revenue

    ₹902 crore

    Net Profit

    ₹110 crore

    Book Value Multiplier

    2.98x

    Promoter Holding

    69.8%

    Dividend Status

    No dividends paid

    Source: Screener

    Highlights:

    ● Maintains profitability.

    ● No dividend payout despite earnings.

    ● Reasonable valuation vs. peers​.

    How to Invest in Small Cap Pharma Stocks?

    To invest in small-cap pharma stocks effectively:

    Open a Demat Account

    Use a demat account for streamlined investment management.

    Research and Analysis

    Evaluate companies based on their R&D pipeline, financial health, and market position.

    Diversification

    Spread investments across multiple stocks to mitigate risk.

    Stay Informed

    Monitor industry trends and upcoming IPOs for potential opportunities.

    Use Investment Tools

    Utilize a brokerage calculator to assess profitability and potential returns.

    Conclusion

    Investing in small-cap pharma stocks offers a compelling opportunity for growth-oriented investors. These stocks provide access to innovative healthcare solutions and can benefit from government initiatives aimed at boosting domestic manufacturing. However, they come with higher risks due to market volatility and regulatory challenges. Investors should conduct thorough research and consider diversifying their portfolios using tools like a brokerage calculator to assess profitability. Additionally, monitoring upcoming IPOs can provide insights into new investment opportunities.

    Other Popular Stocks in India

    Here are some other popular small-cap pharmaceutical companies in India:​

    Windlas Biotech Ltd: Engages in contract development and manufacturing services (CDMO) for the pharmaceutical industry.​

    Krsnaa Diagnostics Ltd: Provides diagnostic services with a wide network across India.​

    Tarsons Products Ltd: Manufactures laboratory plasticware used in pharmaceutical and research laboratories.​

    Anuh Pharma Ltd: Produces APIs and has a presence in both domestic and international markets.​

    Lincoln Pharmaceuticals Ltd: Offers a range of pharmaceutical products and has a growing export footprint.​

    Note: classification of these companies as small-cap is based on their market capitalization as data from Screener.

    Share this article: 

    Frequently Asked Questions

    Published Date : 23 May 2025

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |